NASDAQ:SEELSeelos Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Seelos Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.30 +0.28 (+27.45 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$1.03Now: $1.30▼$1.3950-Day Range$0.44MA: $0.64▼$1.3052-Week Range$0.42Now: $1.30▼$2.87Volume4.10 million shsAverage Volume1.07 million shsMarket Capitalization$58.44 millionP/E RatioN/ADividend YieldN/ABeta1.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSeelos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.33, Seelos Therapeutics has a potential upside of 310.3% from its current price of $1.30.Amount of Analyst CoverageSeelos Therapeutics has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesSeelos Therapeutics has received 41 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSeelos Therapeutics has received 32 “underperform” votes. (Add your “underperform” vote.)Community SentimentSeelos Therapeutics has received 56.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote “Outperform” if you believe SEEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSeelos Therapeutics does not currently pay a dividend.Dividend GrowthSeelos Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seelos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Seelos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.53% of the stock of Seelos Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seelos Therapeutics are expected to grow in the coming year, from ($0.35) to ($0.32) per share. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SEEL Previous Symbol CUSIPN/A CIKN/A Webwww.seelostherapeutics.com Phone646-293-2100Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$380,000.00 Price / Sales153.78 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-51,260,000.00 Net MarginsN/A Return on Equity-373.33% Return on Assets-159.01%Miscellaneous EmployeesN/A Outstanding Shares44,950,000Market Cap$58.44 million Next Earnings Date8/6/2020 (Estimated) OptionableNot Optionable NASDAQ:SEEL Rates by TradingView Receive SEEL News and Ratings via Email Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions How has Seelos Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SEEL shares have increased by 66.7% and is now trading at $1.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Seelos Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seelos Therapeutics. When is Seelos Therapeutics' next earnings date? Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Seelos Therapeutics. How were Seelos Therapeutics' earnings last quarter? Seelos Therapeutics Inc (NASDAQ:SEEL) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.08. View Seelos Therapeutics' earnings history. What price target have analysts set for SEEL? 3 analysts have issued 12-month price targets for Seelos Therapeutics' shares. Their forecasts range from $4.00 to $8.00. On average, they expect Seelos Therapeutics' stock price to reach $5.33 in the next year. This suggests a possible upside of 310.3% from the stock's current price. View analysts' price targets for Seelos Therapeutics. Has Seelos Therapeutics been receiving favorable news coverage? News coverage about SEEL stock has been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Seelos Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutSeelos Therapeutics. Who are some of Seelos Therapeutics' key competitors? Some companies that are related to Seelos Therapeutics include Fortress Biotech (FBIO), Osmotica Pharmaceuticals (OSMT), Northwest Biotherapeutics (NWBO), Affimed (AFMD), Iterum Therapeutics (NRBO), Hookipa Pharma (HOOK), Xeris Pharmaceuticals (XERS), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), IVERIC bio (ISEE), LifeVantage (LFVN), OptiNose (OPTN), Kezar Life Sciences (KZR), Chimerix (CMRX) and Aravive (ARAV). View all competitors. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), vTv Therapeutics (VTVT), Vaxart (VXRT), TrovaGene (TROV), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB) and Sorrento Therapeutics (SRNE). Who are Seelos Therapeutics' key executives? Seelos Therapeutics' management team includes the following people: Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59) What is Seelos Therapeutics' stock symbol? Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL." Who are Seelos Therapeutics' major shareholders? Seelos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (1.13%), BlackRock Inc. (1.17%) and 1492 Capital Management LLC (0.33%). View institutional ownership trends for Seelos Therapeutics. Which major investors are buying Seelos Therapeutics stock? SEEL stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, 1492 Capital Management LLC, and BlackRock Inc.. View insider buying and selling activity for Seelos Therapeutics. How do I buy shares of Seelos Therapeutics? Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Seelos Therapeutics' stock price today? One share of SEEL stock can currently be purchased for approximately $1.30. How big of a company is Seelos Therapeutics? Seelos Therapeutics has a market capitalization of $58.44 million and generates $380,000.00 in revenue each year. What is Seelos Therapeutics' official website? The official website for Seelos Therapeutics is www.seelostherapeutics.com. How can I contact Seelos Therapeutics? Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-293-2100 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
